Ziltivekimab Dosing for Cardiovascular Risk Without Immune Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current IL-6 inhibitors used to treat chronic inflammation often lead to immune suppression, increasing the risk of infections, and there is a need for methods that can reduce cardiovascular morbidity and mortality without causing immune suppression.
Innovation Solution
Administering an IL-6 antagonist at a specific dose and schedule that is sufficient to treat cardiovascular morbidity and mortality, while minimizing immune suppression, by reducing C-reactive protein levels and maintaining adequate neutrophil counts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If IL-6 inhibitors are administered at current dose regimens to treat chronic inflammation, then inflammation is reduced, but immune suppression occurs leading to increased susceptibility to infections
Solution Approach 1:
The patent applies parameter changes by adjusting the dosage and administration schedule of IL-6 inhibitors to achieve optimal therapeutic effect while minimizing immune suppression. Specifically, the patent identifies dose ranges and dosing intervals that reduce inflammation effectively without causing significant neutropenia or increasing infection risk, thereby resolving the contradiction between inflammation control and immune function preservation
2Reliability
If IL-6 inhibitors are used to treat cardiovascular disease, then cardiovascular morbidity and mortality are reduced, but immune suppression increases infection risk
Solution Approach 1:
The patent applies parameter changes by optimizing the dosage and administration schedule of IL-6 inhibitors for cardiovascular disease treatment. The patent identifies specific dose ranges and dosing intervals that achieve cardiovascular benefits while maintaining adequate neutrophil counts and minimizing infection risk, thereby resolving the contradiction between cardiovascular outcome improvement and infection risk reduction
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The disclosure provides methods of treating cardivascular disease, including pateints with atherosclerotic cardiovascular disease and/or chronic kidney disease.. The method comprises administering a therapeutically effective amount of ziltivekimab .